FNAM (Evolutionary Genomics) Cyclically Adjusted FCF per Share: $-0.85 (As of Dec. 2022)


FNAM Evolutionary Genomics Inc FNAM
31 GF Score
Price $0.00
View Full Analysis

What is Evolutionary Genomics Cyclically Adjusted FCF per Share?

Evolutionary Genomics FNAM 31 Cyclically Adjusted FCF per Share is $-0.85 as of Dec. 2022. GuruFocus rates FNAM with a GF Score™ of 31/100.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Evolutionary Genomics's adjusted free cash flow per share for the three months ended in Dec. 2022 was $-0.028. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-0.85 for the trailing ten years ended in Dec. 2022.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-13), Evolutionary Genomics's current stock price is $0.0002. Evolutionary Genomics's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2022 was $-0.85. Evolutionary Genomics's Cyclically Adjusted Price-to-FCF of today is .


Evolutionary Genomics  (OTCPK:FNAM) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Evolutionary Genomics Cyclically Adjusted FCF per Share Related Terms


Evolutionary Genomics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Evolutionary Genomics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evolutionary Genomics Cyclically Adjusted FCF per Share Chart

Evolutionary Genomics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -0.73 -0.75 -0.81 -0.85

Evolutionary Genomics Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.81 -0.83 -0.85 -0.85 -0.85

FNAM vs BXRX, GNCA, XSNX: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Evolutionary Genomics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evolutionary Genomics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evolutionary Genomics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Evolutionary Genomics's Cyclically Adjusted Price-to-FCF falls into.


FNAM
31GF Score
Evolutionary Genomics Inc FNAM
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Evolutionary Genomics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Evolutionary Genomics's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2022 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2022 (Change)*Current CPI (Dec. 2022)
=-0.028/296.7970*296.7970
=-0.028

Current CPI (Dec. 2022) = 296.7970.

Evolutionary Genomics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201303 -0.023 232.773 -0.029
201306 -0.038 233.504 -0.048
201309 -0.031 234.149 -0.039
201312 -0.008 233.049 -0.010
201403 -0.023 236.293 -0.029
201406 -0.069 238.343 -0.086
201409 -0.069 238.031 -0.086
201412 -5.123 234.812 -6.475
201503 -0.032 236.119 -0.040
201506 -0.045 238.638 -0.056
201509 -0.052 237.945 -0.065
201512 0.010 236.525 0.013
201603 -0.065 238.132 -0.081
201606 -0.040 241.018 -0.049
201609 -0.028 241.428 -0.034
201612 -0.055 241.432 -0.068
201703 -0.053 243.801 -0.065
201706 -0.068 244.955 -0.082
201709 -0.036 246.819 -0.043
201712 -0.043 246.524 -0.052
201803 -0.036 249.554 -0.043
201806 -0.040 251.989 -0.047
201809 -0.026 252.439 -0.031
201812 -0.025 251.233 -0.030
201903 -0.021 254.202 -0.025
201906 -0.034 256.143 -0.039
201909 -0.022 256.759 -0.025
201912 -0.029 256.974 -0.033
202003 -0.006 258.115 -0.007
202006 -0.039 257.797 -0.045
202009 -0.079 260.280 -0.090
202012 -0.263 260.474 -0.300
202103 -0.033 264.877 -0.037
202106 -0.016 271.696 -0.017
202109 -0.153 274.310 -0.166
202112 -0.066 278.802 -0.070
202203 -0.030 287.504 -0.031
202206 -0.022 296.311 -0.022
202209 -0.020 296.808 -0.020
202212 -0.028 296.797 -0.028

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-0.85 mean?
Evolutionary Genomics (FNAM) has a Cyclically Adjusted FCF per Share of $-0.85 as of Dec. 2022. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Evolutionary Genomics and its competitors.
Is Evolutionary Genomics' Cyclically Adjusted FCF per Share too high?
Evolutionary Genomics' current Cyclically Adjusted FCF per Share is $-0.85. Overall, Evolutionary Genomics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Evolutionary Genomics' Cyclically Adjusted FCF per Share compare to BXRX and GNCA?
Evolutionary Genomics' Cyclically Adjusted FCF per Share of $-0.85 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Evolutionary Genomics and its competitors. Evolutionary Genomics's current Cyclically Adjusted FCF per Share is $-0.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evolutionary Genomics stock overvalued right now?
Evolutionary Genomics (FNAM) has a current Cyclically Adjusted FCF per Share of $-0.85. The current Cyclically Adjusted FCF per Share is $-0.85. Evolutionary Genomics' overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Evolutionary Genomics (FNAM), the current Cyclically Adjusted FCF per Share is $-0.85 as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evolutionary Genomics Business Description

Address 4220 Morning Star Drive, Castle Rock, CO, USA, 80108
Evolutionary Genomics Inc is involved in the development of a technology platform, the Adapted Traits Platform (ATP), to identify commercially valuable genes that control important traits in animals and plants. It uses the ATP to identify genes to improve crop plant traits such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. The company's platform identifies key genes that have changed successfully to impart new or improved traits. Its primary source of revenue had been contract services revenue for research performed by it on behalf of other commercial entities and grant income received from governmental agencies, industry associations and grant-making foundations for research performed.
31GF Score

Get the complete analysis for FNAM

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price